PERFUSE study – poster SFR Congress December 2019

Mis à jour : 14 nov. 2019

Sanoïa is delivering full-service CRO operations for the PERFUSE study. This non-interventional, late-phase study investigates the persistence (in other words how many patients continue on treatment) and immunogenicity (meaning the ability of a foreign substance to enter a person's body and cause an immune response) of FLIXABI™ (infliximab) in patients suffering from chronic inflammatory rheumatism.

As part of the electronic poster session at the “32th French Congress on Rheumatology” in Paris this December (Monday, December 9) recent findings regarding treatment with the infliximab biosimilar SB2 will be presented.


e-Health Services SAS


  • LinkedIn Social Icône


(French Clinical Research Association)

Sanoïa is an agile Contract Research Organization for tailor-made Real-Life studies.